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More chemicals, more drug targets 
and smaller testing wells are here. 
But someone has to determine the 
results of all those assays. Measuring 
one assay at a time may not be fast 
enough, and that is where Imaging 
Research Inc. (IRI; St Catherines, 
Canada) steps in. Their giant lens 
captures the image of an entire 
screening plate, and proprietary 
software defines the wells and the 
individual assay results. 
From tissues to Tundra 
Peter Ramm of Brock University (St 
Catherines, Canada) is the founder of 
IRI, and the early incarnation of the 
company reflected his research in 
neuroscience. Thus one aim of the 
IRI imaging system was to visualize 
the binding of labeled ligands to 
large brain sections. IRI developed 
imaging systems and software for the 
quantitative analysis of these images, 
but the imaging optics remained 
somewhat conventional. 
In the hardware area, Ramm 
realized that there was a new 
opportunity. “We were aware of 
changes in the priorities of the 
pharmaceutical companies,” he says. 
“Screening hadn’t required imaging, 
but with these large libraries imaging 
seemed a reasonable approach to 
increase throughput.” And IRIS 
experience in imaging entire brain 
sections could help their attempts to 
image entire assay plates. The 
Tundra system was born. 
Big optics 
Tundra is not a microscope. The 
combination of its key components - 
the custom-made ‘Borealis’ lens and a 
charge coupled device (CCD) - end Figure 1 
up being slightly demagnifying. The 
CCD converts incoming photons into 
electrons, and is cooled to reduce 
spontaneous activity, and thinned to 
increase sensitivity. 
But the pride of the Tundra is the 
lens. The Borealis measures 12 cm in 
diameter, includes 13 separate 
lenses, and weighs in at 40 pounds. 
The combination of its size and large 
aperture means that it collects far 
more light than a normal lens. The 
Borealis is also telecentric, meaning 
that it can peer directly into all the 
wells of a plate. Normal lenses suffer 
from parallax, with light .being 
distorted (the round tops of distant 
wells become ovals) and lost (well 
walls shade the contents of wells). 
All fluorescence detectors fight 
against background. The microscope 
solution had been to make lenses 
epifluorescent, but before Borealis 
no epifluorescent macrolens was 
available. Without epifluorescence, 
the excitation light comes from one 
side and the filtered emission light is 
collected on the other. Unfortunately 
the filters are imperfect and the 
emission light can be a thousandfold 
weaker than the excitation light. “It’s 
like seeing a star against the daylight 
sky,” says Ramm. “But in 
epifluorescence you shine the 
excitation light out of the lens, away 
from the detector, and see only the 
emitted light coming back. Now 
you’re looking at the stars against the 
night sky.” 
IRI has sold more than 20 Tundra 
units at over $200,000 each. A recent 
Tundra customer was the Institute 
for Chemistry and Cell Biology at 
Harvard Medical School (Boston, 
Massachusetts). Randy King, an 
independent fellow at the Institute, 
was impressed by the Tundra. “It’s 
juiced at both the light-gathering 
end and the camera end to be as 
sensitive as you can get right now,” 
he says. “There’s a big gap between 
them and what else is out there.” 
Most drug companies are in the 
process of converting their screening 
format from 96- to 384-well.plates, 
The IRI system can measure fluorescence 
(top), luminescence (bottom) and 
absorbance. Image courtesy of IRI. 
but King believes that the Tundra will 
handle his 6144-well plates quite 
happily. Based on the pixel density of 
the CCD, this is approximately the 
limit for the current system, although 
Ramm says that IRI is considering a 
high resolution system to look at 
smaller areas of genome microarrays. 
On June 19, Amersham Pharmacia 
Biotech Ltd (APB) bought a 
controlling interest in IRI, and 
Tundra became a part of Leadseeker, 
a new screening package. 
Leadseeker, to be formally launched 
in September, will be considerably 
more expensive than Tundra, and will 
include fluidic dispensing and robotic 
delivery of plates. Leadseeker assays 
have been designed by IRI and APB. 
One of the new assays in 
Leadseeker’s repertoire will be the 
scintillation proximity assay (SPA), 
which is proprietary to APB. In SPA,. 
radioactive ligands bind to proteins 
on scintillant-containing beads, 
causing very low levels of light to be 
emitted. SPA is a homogeneous 
assay, valuable because chemicals 
can usually be tested without any 
washing or filtering steps. Adding 
SPA capability would, says King, “be 
a pretty impressive feat.” 
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Alternative views 
IRI is in a crowded market. The 
traditional detectors are scanners that 
use photomultiplier tubes (PMTs) to 
detect signal from a single well. 
Current examples include the Victor2 
($23,500-$50,000 from EG&G 
Wallac, Gaithersburg, Maryland), and 
the Analyst, which also does 
fluorescence polarization (-$100,000 
from LJL Biosystems, Sunnyvale, 
California). Drug screens are a 
constant trade-off between speed and 
sensitivity, and PMTs tend to be more 
sensitive but slower than CCDs. 
Next year, Wallac will release the 
Viewlux, a CCD-based plate imager 
for time-resolved fluorescence. 
“When you move beyond the 384- 
well format you start to move beyond 
the capabilities of the PMTs,” says 
John Westerfeld, Wallac product 
manager. “Sensitivity is a problem, 
and [the detection areas of the PMTs] 
start spilling over to adjacent wells.” 
One way to get around this 
density problem is to feed the signal 
to the PMTs using a fiber optic array. 
Aurora Biosciences Corporation (La 
Jolla, California) and its corporate 
partners use a fiber optic array of up 
to 192 elements to screen 3456-well 
plates. “There’s no way that a 
telecentric lens system can be more 
sensitive than a fiber array that is 
designed for fluorescence detection, 
and is within a hundred microns of 
the source,” says Harry Stylli, 
Aurora’s vice president for screening 
technology. 
Aurora uses both CCDs and 
PMTs, but Stylli believes that in the 
end CCDs will win out. “In the next 
generation the dominant [systems] 
will be camera-based. You can sell 
them for more, they are better in low 
light, they have the potential to 
image whole areas, and they can do 
imaging not just detection.” 
Molecular Devices Corporation 
(Sunnyvale, California) already has a 
plate imager on the market called 
FLIPR (fluorescent imaging plate 
reader). “It was designed to do a 
specific thing and to do it well,” says 
Simon Pitchford, product marketing 
manager. He estimates that 80% of 
FLIPR machines are used for time- 
dependent detection of calcium 
levels, with most other assays 
involving pH or membrane 
polarization changes. All these assays 
involve dyes with relatively intense 
fluorescence, so FLIPR can get away 
with a regular sized lens. 
FLIPR can deliver agonists or 
antagonists simultaneously to all wells 
of a 96-well plate, and excitation and 
imaging of a plate takes as little as one 
second. A laser is split into eight 
parallel scans for more rapid 
excitation, and a CCD camera takes 
an image of the entire plate. Pitchford 
claims that oblique illumination 
keeps the light at the base of the well, 
so background fluorescence is 
reduced. Imaging through a mask and 
from the bottom of the well reduces 
the problem of parallax. 
The current version of FLIPR 
goes for -$250,000, and has integrated 
fluid delivery. A 384-well version, to 
be released in September, will add 
robotics handling of the plates. 
Carl Zeiss Jena GmbH (Jena, 
Germany) has increased throughput 
simply by using multiple detectors: 96 
micro-objectives, which read out in 
parallel to a CCD. “The advantage of 
that approach is that you can use 
lenses with higher numerical aperture 
and so greater collection efficiency,” 
says Martin Gluch, project leader for 
the Ultra-High-Throughput System 
at Zeiss. The unnamed and unpriced 
system, to be launched in August, can 
also handle 384- and 1536-well plates 
in multiple reads, and has integrated 
robotics and fluid handling. 
More detailed information 
The Zeiss system is designed to be 
used in combination with the High 
Content Screening (HCS) system 
from Cellomics Inc. (Pittsburgh, 
Pennsylvania). This system uses more 
conventional microscope optics to 
image a single well of a plate. The key 
to HCS is the software, which 
analyzes a statistically significant 
number of cells (typically 50-300) and 
reports on the movement of molecules 
(nuclear localization, receptor 
internalization) or cellular morphology 
changes (hypertrophy, apoptosis). It 
takes -20 minutes to screen a 96-well 
plate, and so is best suited to analyzing 
the hits obtained using the faster Zeiss 
machine. In one day of screening, the 
Cellomics system should be able to 
profile the 1000 hits identified from 
the 100,000 chemicals screened by the 
Zeiss system. 
EVOTEC BioSystems GmbH 
(Hamburg, Germany) gets its 
quantitative information by looking at 
the motion of single molecules. The 
EVOscreen uses fluorescence 
correlation spectroscopy (FCS) to 
determine whether a ligand is moving 
quickly (unbound) or slowly (bound to 
a large target). A laser is focused into a 
volume approximately the size of an 
Eschetichia co/i cell (1 fl or 10-15 1). For 
solutions in the micromolar to 
picomolar range, the number of 
molecules in this volume is small 
enough that the motion of single 
fluorescent molecules can be 
measured by looking at the molecules’ 
photon showers, using avalanche 
photodiodes. The result is affinity 
data, and on and off rates, collected at 
the rate of one second per well. 
Two EVOscreen systems have 
been sold for -$15 million each, and 
once another two are sold the 
company will be devoted to in-house 
screening. The off-the-shelf Zeiss 
ConfoCor instrument has the same 
optics, but it lacks the EVOscreen 
detection and software units. 
The EVOTEC system tests only 
small molecule binding events, but it 
has the advantage of always being 
ready for more miniaturization. “With 
conventional fluorescence you need 
to collect fluorescence from as many 
molecules as possible,” explains 
Bjoern Lindemann, vice president for 
corporate communications at 
EVOTEC. “But with FCS we are 
looking at single molecules, so 
miniaturization is not a problem.” 
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